Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3):1602265. doi:10.1183/13993003.02265-201628889106
   PubMed Web of Science ®Google Scholar
• Miravitlles M, D’Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17(1):112. doi:10.1186/s12931-016-0425-527613392
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012;7:95–99. doi:10.2147/COPD
   Google Scholar
• Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(12):1301‒1306. doi:10.1164/rccm.201202-0223OC
   Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847‒852. doi:10.1136/thorax.57.10.847
   Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, ECLIPSE Investigators, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 365;2011:1184‒1192. doi:10.1056/NEJMoa1105482
   Web of Science ®Google Scholar
• Oliveira AS, Munhá J, Bugalho A, et al; GI DPOC Grupo de Interesse na Doenca Pulmonar Obstrutiva Cronica. Identification and assessment of COPD exacerbations. Pulmonology. 2018;24:42‒47.
   Web of Science ®Google Scholar
• Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67:238‒243. doi:10.1136/thoraxjnl-2011-200768
   Web of Science ®Google Scholar
• Perera WR, Hurst JR, Wilkinson TM, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007;29:527‒534. doi:10.1183/09031936.00092506
   Web of Science ®Google Scholar
• Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:943‒950. doi:10.1164/rccm.201412-2269OC
   Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093‒1103. doi:10.1056/NEJMoa1008378
   Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222‒2234. doi:10.1056/NEJMoa1516385
   Web of Science ®Google Scholar
• Boer LM, Bischoff EW, Borgijink X, et al. ‘Exacerbation-free time’ to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study. NPJ Prim Care Respir Med. 2018;28(1):12. doi:10.1038/s41533-018-0079-529615628
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6(5):337‒344. doi:10.1016/S2213-2600(18)30102-4
   Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671‒1680. doi:10.1056/NEJMoa1713901
   Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81‒90.
   Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe COPD: pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018;198(10):1268‒1278. doi:10.1164/rccm.201712-2493OC
   Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117‒126. doi:10.1016/S2213-2600(18)30006-7
   Web of Science ®Google Scholar
• Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371:2013‒2018. doi:10.1016/S0140-6736(08)60869-7
   Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, et al; PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187‒194. doi:10.1016/S2213-2600(13)70286-8
   Web of Science ®Google Scholar
• Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Exp Rev Respir Med. 2007;1:307‒316.
   Google Scholar
• Dal Negro RW, Wedzicha JA, Iversen M; RESTORE group, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50:1700711. doi:10.1183/13993003.00711-201729025888
   PubMed Web of Science ®Google Scholar
• Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med. 2014;108:729‒736. doi:10.1016/j.rmed.2014.03.002
   Web of Science ®Google Scholar
• Raluy-Callado M, Lambrelli D, MacLachlan S, Khalid JM. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013. Int J Chron Obstruct Pulmon Dis. 2015;10:925‒937.
   Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117:398–401. doi:10.1378/chest.117.5_suppl_2.398S10669681
   PubMed Web of Science ®Google Scholar
• Keene ON, Calverley PM, Jones PW, Vestbo J, Anderson JA. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J. 2008;32:17‒24.
   Web of Science ®Google Scholar
• Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59. doi:10.1186/1465-9921-10-5919566934
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Vestbo J, Anderson JA, et al. Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. Am J Respir Crit Care Med. 2017;195(7):881‒888. doi:10.1164/rccm.201607-1421OC
   Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD. 2017;14:552‒563. doi:10.1080/15412555.2017.1347918
   Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139‒1147. doi:10.1164/rccm.200801-145OC
   Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016;374(19):1811‒1821. doi:10.1056/NEJMoa1505971
   PubMed Web of Science ®Google Scholar
• Labonté LE, Tan WC, Li PZ, et al; Canadian Respiratory Research Network; CanCOLD Collaborative Research Group. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285‒298. doi:10.1164/rccm.201509-1795OC
   PubMed Web of Science ®Google Scholar
• Johnson K, McEvoy CE, Naqvi S, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016;11:799‒807.
   Web of Science ®Google Scholar
• Calverley PM, Spencer S, Willits L, Burge PS, Jones PW, Group IS. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003;124(4):1350‒1356. doi:10.1378/chest.124.4.1350
   Web of Science ®Google Scholar
• Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552‒1560. doi:10.1016/S0140-6736(05)66456-2
   Web of Science ®Google Scholar
• Calverley PM, Kuna P, Monso E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858‒1868. doi:10.1016/j.rmed.2010.09.008
   Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076‒1084. doi:10.1016/S0140-6736(18)30206-X
   Web of Science ®Google Scholar
• Han MK, Quibrera PM, Carretta EE, SPIROMICS investigators, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 5;2017:619‒626. doi:10.1016/S2213-2600(17)30207-2
   Web of Science ®Google Scholar
• Calverley PM, Tetzlaff K, Dusser D, et al. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. Int J Chron Obstruct Pulmon Dis. 2017;12:3391‒3405. doi:10.2147/COPD
   Web of Science ®Google Scholar
• Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540‒1551. doi:10.1164/rccm.201710-2028PP
   Web of Science ®Google Scholar